New lab brings genomics options closer to UK users
Azenta, Inc announces the inauguration of its latest Genomics Laboratory in Oxford, UK, marking a signifi cant expansion of its renowned GENEWIZ Multiomics & Synthesis Solutions in the UK market. This state-of-the-art facility brings Azenta closer to UK-based researchers, offering advanced next-generation sequencing (NGS) platforms and a team of expert scientists from Oxford.
“We’re excited to inaugurate our Oxford laboratory, providing cutting-edge NGS technology to researchers in the UK,” stated Dr Ginger Zhou, President of Azenta’s Multiomics business unit. “This new facility not only enhances our global presence but also grants researchers access to local expertise and advanced resources. Our Oxford team comprises top-tier scientists deeply rooted in the local scientifi c community.”
The grand opening ceremony, hed on 25 April 2024 featured a ribbon-cutting ceremony, laboratory tours, and a celebratory reception attended by key stakeholders, local scientifi c community members, distinguished guests and Azenta executives.
Dr David Buck, Director of Lab Services Oxford, remarked: “Our new lab underscores our commitment to supporting UK researchers by delivering high-quality data faster, driving advancements in critical fi elds such as diabetes, infectious diseases, Alzheimer’s, and more. We are excited about the collaboration and engagement with the scientifi c community and eager to contribute to their success.”
Dr John Todd, Professor of Precision Medicine at the University of Oxford, who attended the opening event, commented: “Having a remarkable genomics facility like the one Azenta has opened at our doorstep enables us to work faster, achieve more with higher accuracy, and enhance medical research discovery for patient benefi t.”
The Oxford Genomics Laboratory prioritises customer convenience, offering a network of GENEWIZ collection points and free same-day dry ice sample collection in Oxford and Cambridge, simplifying the sample submission process for researchers. The lab provides a comprehensive suite of NGS
The ribbon-cutting at the grand opening ceremony.
services, including library preparation, sequencing, bioinformatics analysis with UK-based data storage, and soon-to-be-added DNA/RNA extraction capabilities, all supported by experienced PhD-level study managers guiding projects from inception to delivery.
Azenta’s GENEWIZ is equipped with cutting-edge NGS platforms globally, enabling users to stay at the forefront of scientifi c innovation. These platforms include Illumina NovaSeqTM X Plus, PacBio Revio, Oxford Nanopore Technologies GridION, PromethION 2 Solo, 10x Genomics Chromium X, Nanostring GeoMx® & nCounter®, and Olink® Protein Biomarker Detection.
More information online:
www.azenta.com
62652pr@reply-direct.com
Project assesses approach to reducing cell therapy costs
A UK and Swiss consortium comprising the Cell and Gene Therapy Catapult (CGT Catapult), Securecell, a high-tech solution provider and DataHow AG, specialised in data analytics and bioprocess modelling, has been awarded over £750,000 to integrate new digitisation and process analytical technologies (PATs) into the manufacturing of cell and gene therapies. Funded by the national innovation agencies Innovate UK and Innosuisse, the project aims to make advanced therapies more affordable to healthcare systems by reducing the cost of manufacturing these therapies.
During the project, Securecell will integrate PATs into its bioprocess sampling system and software. The system will be implemented into the CGT Catapult’s PAT laboratory and demonstrated during the production of an adeno-associated virus (AAV). In collaboration with DataHow, the data produced will be used to explore the benefi ts of using hybrid modelling approaches, such as digital twins, during the manufacturing of advanced therapies.
Matthew Durdy (Credit: CGT Catapult)
“The unique expertise of each collaborator will be combined to develop innovative solutions for automated on-line analysis within the ATMP manufacturing space,” commented Carlo Andretta, Chief Executive Offi cer at Securecell. “This project will set new standards when it comes to workfl ow automation, process digitalisation and advanced data analytics in ATMP manufacturing and benefi t the patients of tomorrow.”
Moritz von Stosch, Chief Innovation Offi cer at DataHow, added: “The collaboration between the CGT Catapult, Securecell and DataHow brings together a powerful combination of expertise in CGT processes, data management and model-based process development, which offers a unique opportunity to reimagine the development and operation of CGT processes. By showcasing how digital technologies can mitigate risks in CGT process development and enhance
Matthew Durdy, Chief Executive of the CGT Catapult, said: “This project is an excellent example of how the advanced therapies sector can use new technologies to make highly complex and regulated processes more effi cient and cost-effective, which is vital when it comes to ensuring that these therapies are affordable and accessible to healthcare services across the globe.”
outcomes without requiring additional resources, we can create a pivotal ‘aha moment.’ This moment could mark a shift where digital transformation evolves from a theoretical concept to a practical reality.”
More information online:
ilmt.co/PL/ZbjW 62638pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
